MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) lobbying for MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$530,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Texas

Official filing document

Lobbyists on this filing 1

BRIAN BRANTON New on this filing

Previously held: Chief of Staff, Congressman Polis; Chief of Staff, Congressman Sestak; Legislative Director, Congressman Wu; Legislative Counsel, Congressman Holt; Legislative Assistant, Congresswoman Mink

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 5

Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 11

HR 3521
Clinical Trial Modernization Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 2484
Seniors’ Access to Critical Medications Act of 2025
HR 879
Medicare Patient Access and Practice Stabilization Act of 2025
HR 2120
ROCR Value Based Program Act
S 1816
Improving Seniors’ Timely Access to Care Act of 2025
HR 3514
Improving Seniors’ Timely Access to Care Act of 2025
HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 3164
Ensuring Community Access to Pharmacist Services Act
HR 2444
Promoting Resilient Supply Chains Act of 2025
S 257
Promoting Resilient Supply Chains Act of 2025

Lobbying activity 4

Health Issues

H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).

Medicare/Medicaid

H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.

Pharmacy

H.R. 3164, Ensuring Community Access to Pharmacist Services Act.

Manufacturing

H.R. 2444, Promoting Resilient Supply Chains Act; S.257, Promoting Resilient Supply Chains.